Therapies to revascularize ischemic tissue have long been a goal for the treatment of vascular disease and other disorders. Therapies using stem cell factor (SCF), also known as a c-Kit ligand, had great promise for treating ischemia for myocardial infarct and stroke, however clinical development for SCF was stopped due to toxic side effects including mast cell activation in patients. We recently developed a novel therapy using a transmembrane form of SCF (tmSCF) delivered in lipid nanodiscs.
View Article and Find Full Text PDFPhilos Trans R Soc Lond B Biol Sci
September 2023
Hundreds (if not thousands) of multisensory studies provide evidence that the human brain can integrate temporally and spatially discrepant stimuli from distinct modalities into a singular event. This process of multisensory integration is usually portrayed in the scientific literature as contributing to our integrated, coherent perceptual reality. However, missing from this account is an answer to a simple question: how do confidence judgements compare between multisensory information that is integrated across multiple sources, and multisensory information that comes from a single, congruent source in the environment? In this paper, we use the sound-induced flash illusion to investigate if confidence judgements are similar across multisensory conditions when the numbers of auditory and visual events are the same, and the numbers of auditory and visual events are different.
View Article and Find Full Text PDFTherapies to revascularize ischemic tissue have long been a goal for the treatment of vascular disease and other disorders. Therapies using stem cell factor (SCF), also known as a c-Kit ligand, had great promise for treating ischemia for myocardial infarct and stroke, however clinical development for SCF was stopped due to toxic side effects including mast cell activation in patients. We recently developed a novel therapy using a transmembrane form of SCF (tmSCF) delivered in lipid nanodiscs.
View Article and Find Full Text PDFRegenerative therapeutics for treating peripheral arterial disease are an appealing strategy for creating more durable solutions for limb ischemia. In this work, we performed preclinical testing of an injectable formulation of syndecan-4 proteoliposomes combined with growth factors as treatment for peripheral ischemia delivered in an alginate hydrogel. We tested this therapy in an advanced model of hindlimb ischemia in rabbits with diabetes and hyperlipidemia.
View Article and Find Full Text PDFTherapies to revascularize ischemic tissue have long been a goal for the treatment of vascular disease and other disorders. Therapies using stem cell factor (SCF), also known as a c-Kit ligand, had great promise for treating ischemia for myocardial infarct and stroke, however clinical development for SCF was stopped due to toxic side effects including mast cell activation in patients. We recently developed a novel therapy using a transmembrane form of SCF (tmSCF) delivered in lipid nanodiscs.
View Article and Find Full Text PDF